230 related articles for article (PubMed ID: 23504768)
21. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Moroni M; Veronese S; Benvenuti S; Marrapese G; Sartore-Bianchi A; Di Nicolantonio F; Gambacorta M; Siena S; Bardelli A
Lancet Oncol; 2005 May; 6(5):279-86. PubMed ID: 15863375
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor inhibitors and colorectal cancer.
Meyerhardt JA; Fuchs CS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):35-8. PubMed ID: 15685832
[TBL] [Abstract][Full Text] [Related]
23. [Cetuximab].
Takiuchi H
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
[TBL] [Abstract][Full Text] [Related]
24. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.
Rosati G; Aprile G; Cardellino GG; Avallone A
J Geriatr Oncol; 2016 Mar; 7(2):134-41. PubMed ID: 26897044
[TBL] [Abstract][Full Text] [Related]
25. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
26. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
28. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL
Eur J Cancer; 2011 Jun; 47(9):1343-54. PubMed ID: 21550229
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Gomez D; De Rosa A; Addison A; Brooks A; Malik HZ; Cameron IC
Int J Surg; 2013; 11(7):507-13. PubMed ID: 23660586
[TBL] [Abstract][Full Text] [Related]
30. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
[TBL] [Abstract][Full Text] [Related]
31. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
Elez E; Argilés G; Tabernero J
Curr Treat Options Oncol; 2015 Nov; 16(11):52. PubMed ID: 26374340
[TBL] [Abstract][Full Text] [Related]
32. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
Wu M; Rivkin A; Pham T
Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
[TBL] [Abstract][Full Text] [Related]
33. Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.
Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
[TBL] [Abstract][Full Text] [Related]
34. Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw PH; Adams RA
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
[TBL] [Abstract][Full Text] [Related]
35. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
[TBL] [Abstract][Full Text] [Related]
36. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
[TBL] [Abstract][Full Text] [Related]
37. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
Cohenuram M; Saif MW
Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
[TBL] [Abstract][Full Text] [Related]
38. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B
Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
[TBL] [Abstract][Full Text] [Related]
39. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
[TBL] [Abstract][Full Text] [Related]
40. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
Lau SC; Chung V; Lim D; Shibata S
J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
